JRJulie Roiz

Julie Roiz

*This is an algorithmically generated author record based on publicly available information.

Julie Roiz has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Annual vaccination with BNT162b2 in Germany can avoid substantial clinical and economic burden of COVID-19 disease

    by Amy Barber, Julie Roiz, Sam Greenall, Edward Church, Andrea Schmetz, Stefan Riebel, Jingyan Yang, Oliver Witzke, Afschin Gandjour

    To quantify the clinical and economic burden of Coronavirus disease 19 (COVID-19), and burden potentially avoided with annual vaccination, in German adults in an endemic setting. A decision tree model was constructed to estimate the clinical and economic impact of COVID-19 and projected burden avoided with BNT162b2, a seasonally adapted mRNA vaccine against severe COVID-19 disease. The majority of cost inputs and clinical event probabilities were informed by German real-world evidence from seasons 2022/23 and 2023/24. Vaccine efficacy was derived from US and German studies. Long/Post COVID impact was assessed in scenario analysis. The model estimated up to 20.8 million symptomatic infections per year in adults, including 7.5 million in people aged 60+, and 6.0 million in comorbid adults. This translates to an estimated 198,598 hospitalizations and 24,626 COVID-attributable deaths, with 93.6% of deaths occurring in people aged 60+. The total economic burden including productivity loss was estimated at €1.4 billion in people aged 60+, €2.0 billion in comorbid adults, and €3.9 billion in all working adults. Long/Post COVID increased the economic burden by 1.7 times. Assuming vaccination of 100% of recommended groups, 11.0 million symptomatic infections could be prevented, with the greatest impact in people aged 60+ (estimated 110,362 hospitalizations and 13,685 deaths avoided). For people aged 60+, comorbid adults, and all working adults, the number needed to vaccinate to prevent one symptomatic infection was 7, 4, and 4 people; to prevent one hospitalization, 231, 2,363, and 4,549; and to avoid one death, 1,862, 19,055, and 36,683, respectively. COVID-19 imposes a substantial clinical and economic burden on the German population, which could be mitigated with an expanded COVID-19 vaccination program. Further research into Long/Post COVID is needed. Our study presents considerations highlighting the value of broad vaccination especially for working adults.


  • Open Access

    Experimental determination of pesticide processing factor during extraction of maize germ oil

    by Patrick Carré, Florence Lacoste, Jean-Noël Arnaud, Loïc Leitner, Julie Roiz

    As there is a lack of regulations on pesticide levels in crude oils, this study aimed to evaluate transfer factors for extrapolating concentration limits established for maize kernels to the crude oils extracted from their germs. Maize kernels were spiked with 4 organophosphates insecticides (chlorpyriphos, chlorpyriphos-methyl, fenitrothion, pirimiphos-methyl), 2 pyrethroids (cypermethrin and deltamethrin) and a pyrethroid synergist, piperonyl butoxide (PB) targeting a dose of 1 mg/kg grain. The kernels were transformed in a pilot starch-mill to separate the germs (wet-milling) then these germs underwent an oil extraction process in a mini-pilot comprising a thermal conditioning stage, a mechanical extraction followed by a solvent extraction and a desolventization-toasting stage for the meal. Analyses were carried out by gas chromatography coupled to MS/MS detector. The pesticides content was measured on kernels, spiked kernels, germ, crude oil and meal. Surprisingly, a significant difference in behavior was observed between organophosphates and pyrethroids in the transition from grain to germ. For the former, the applied pesticides were recovered at levels between 48% and 81% in the germ, compared to only 9–11% for the latter and 31% for PB. It has been shown by means of acetonitrile washing on spiked seeds that the pyrethroids remained bound to the hydrophobic cuticle of the grains. On the other hand, from the germ to the oil, the initial hypothesis of an almost total transfer of the pesticides in the fat fraction of the material was confirmed. The germ to meal concentration ratios were on average 0.019, 0.065 and 0.109 for organophosphates, PB and pyrethroids respectively. In the same order, the concentration ratios between germ and crude oil were 1.87, 1.98 and 2.17. Grain to final oil transfer factors ranged from 7.4 to 12.7 for organophosphates, 4.8 for PB and 1.4 and 1.7 for cypermethrin and deltamethrin respectively.


  • Open Access

    Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model

    by Alexia Kieffer, Matthieu Beuvelet, Aditya Sardesai, Robert Musci, Sandra Milev, Julie Roiz, Jason K H Lee

    Background: Respiratory syncytial virus (RSV) is associated with substantial morbidity in the United States, especially among infants. Nirsevimab, an investigational long-acting monoclonal antibody, was evaluated as an immunoprophylactic strategy for infants in their first RSV season and for its potential impact on RSV-associated, medically attended lower respiratory tract illness (RSV-MALRTI) and associated costs. Methods: A static decision-analytic model of the US birth cohort during its first RSV season was developed to estimate nirsevimab’s impact on RSV-related health events and costs; model inputs included US-specific costs and epidemiological data. Modelled RSV-related outcomes included primary care and emergency room visits, hospitalizations including intensive care unit admission and mechanical ventilations, and RSV-related mortality. Results: Under current standard of care, RSV caused 529 915 RSV-MALRTIs and 47 281 hospitalizations annually, representing $1.2 billion (2021 US dollars [USD]) in costs. Universal immunization of all infants with nirsevimab is expected to reduce 290 174 RSV-MALRTI, 24 986 hospitalizations, and expenditures of $612 million 2021 USD. Conclusions: An all-infant immunization strategy with nirsevimab could substantially reduce the health and economic burden for US infants during their first RSV season. While this reduction is driven by term infants, all infants, including palivizumab-eligible and preterm infants, would benefit from this strategy.